Hyderabad, Feb 18 (TNT): BioAsia 2026, the 23rd edition of Asia’s premier life sciences and health-tech forum, concluded here on Wednesday with record participation, reinforcing Telangana’s position as a global hub for life sciences and TechBio innovation.
The event witnessed over 4,500 delegates and visitors, the highest ever including international delegates and industry leaders.
Organisers said more than 4,000 high-impact B2B meetings were facilitated during the summit, paving the way for collaborations and investment opportunities.
The valedictory session was preceded by a fireside chat with Telangana Industries and Commerce Minister D. Sridhar Babu, who outlined the roadmap under Rising Telangana Vision 2047 and the state’s ambition to become a $3 trillion economy.
The closing ceremony was attended by Special Chief Secretary (Industries and Commerce) Sanjay Kumar, former Special Chief Secretary B. P. Acharya, and Managing Director, BIRAC, Jitendra Kumar, among other dignitaries.
Addressing the gathering, Sridhar Babu said BioAsia 2026 was the most successful edition so far and underscored Telangana’s growing prominence in the global life sciences and TechBio ecosystem.
Referring to the theme, “TechBio Unleashed: AI, Automation, and the Biology Revolution,” he said the convergence of biology and cutting-edge technologies would drive the next phase of healthcare transformation.
He highlighted significant international participation this year, including companies from France, Indonesia and the United States, and noted that global pharmaceutical major Novartis reaffirmed Hyderabad as a key hub for investment and innovation.
He said the state’s Next Gen Life Sciences Policy 2026–30 is designed to attract global capital, talent and expertise while improving patient outcomes.
Sanjay Kumar said BioAsia reflects Telangana’s vision to catalyse industry growth through innovation and cross-border collaboration.
He emphasised the state’s focus on advanced therapeutics, digital health, precision medicine, AI-driven drug discovery and CRDMO innovation to build a globally competitive ecosystem.
More than 120 startups were shortlisted by an eminent jury for BioAsia 2026, with over 40 innovative startups showcasing solutions across MedTech, medical devices, biopharma, cell and gene therapy, AI and ML, nutraceuticals and biomarkers.
The BioAsia 2026 Innovation Awards were presented to Achala Health Services Private Limited, Exquinz Life Sciences Pvt Ltd, Helex, Natural Solutions & Nutraceuticals Pvt Ltd, and Sree Guravey Life Sciences OPC Pvt Ltd for their disruptive contributions to the sector.
The event featured global experts including Prof. Bruce L. Levine (University of Pennsylvania), Dr. Howard Y. Chang (Amgen, USA), Pushmeet Kohli (Google DeepMind, UK) and Madeleine Roach (Sanofi, France), who shared insights on AI-driven biomedical discovery, next-generation biologics, CRDMO innovation and resilient healthcare systems.
Panel discussions on the final day focused on innovation-led Global Capability Centres (GCCs), India’s transition from manufacturing to innovation-driven life sciences leadership, and financing TechBio and deep-tech manufacturing.
With strengthened global engagement and investor interest, organisers said BioAsia 2026 has set the stage for an even more impactful edition next year, continuing its role as a bridge between innovation and enterprise in the life sciences sector.
TNT TS
Leave a Reply